RxDoctor Payments Data

Regina McPherson, MD

Hospice and Palliative Medicine · Chapel Hill, NCNPI 1649634775

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 33.1% of the total. Reporting peaked in 2021 at $282 and has fallen 93.1% since, to $20 in 2024. Among hospice and palliative medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$426in general payments, 2019–2025

Across 28 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$141
  • AstraZeneca$65
  • E.r. Squibb & Sons, L.L.C.$42
  • Pfizer$39
  • Novo Nordisk$32
  • Exact Sciences$24
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$426 in reported general payments places this provider in the 90th percentile of 45 hospice and palliative medicine providers in North Carolina.

See all hospice and palliative medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$48,676
Medicare patients
183
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$29,256
OzempicSemaglutide14$20,909
JardianceEmpagliflozin11$18,563
SynthroidLevothyroxine Sodium17$1,699
Gabapentin82$1,626
Atorvastatin Calcium103$993
ValacyclovirValacyclovir Hcl12$596
Albuterol Sulfate HfaAlbuterol Sulfate24$540
Metoprolol Succinate35$529
Lisinopril43$473
Omeprazole17$461
Levothyroxine Sodium45$448
Rosuvastatin Calcium41$433
Losartan Potassium34$359
Ezetimibe23$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$29,25619 claims
Novo NordiskOzempic$32$20,90914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 hospice and palliative medicine providers in North Carolina.

Other hospice and palliative medicine in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →